Testing the Addition of Tazemetostat to the Immunotherapy Drug, Pembrolizumab (MK-3475), in Advanced Urothelial Carcinoma

NCT03854474 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

30

Enrollment

NIH

Sponsor class

Conditions

Locally Advanced Urothelial Carcinoma
Metastatic Urothelial Carcinoma
Stage III Bladder Cancer AJCC v8
Stage IV Bladder Cancer AJCC v8

Interventions

PROCEDURE: Biospecimen Collection
PROCEDURE: Computed Tomography
PROCEDURE: Magnetic Resonance Imaging
BIOLOGICAL: Pembrolizumab
DRUG: Tazemetostat

Sponsor

National Cancer Institute (NCI)